Skip to main content
. 2014 Dec 11;8(1):33–41. doi: 10.1007/s12307-014-0161-7

Fig. 3.

Fig. 3

PSA change during therapy. a Maximal PSA reduction compared to baseline for patients with PSA response, with stable disease and PSA progress. b the PSA change from baseline or LOCF. Patients with PSA response: black bars, patients with stable disease: grey bars, patients with PSA progress: white bars. PSA Prostate-specific antigen, LOCF Last observation carried forward, *Patients who entered the expansion phase of the study